Larry Weiner is a biopharmaceutical operations leader with significant experience with Manufacturing, CMC, Program Management, Supply Chain, Project Management, Facilities and Engineering. Larry leads Manufacturing, Engineering and CMC operations at the regenerative medicine division of Sumitomo Pharma America (formerly Enzyvant Therapeutics). Larry led Technical Operations at Unum Therapeutics and Late Stage Program Management and Real Estate & Facilities operations at Indigo. As the Senior Director of Strategic Programs and Program Management at Biogen, innovation program responsibilities included leading drug substance, drug product, device, and new technology innovation initiatives that addressed significant business opportunities and/or were disruptive to the industry. Led the teams that established Biogen's gene therapy, oligonucleotide, and drug product operations strategies. Program management responsibilities included CMC, new product launches, and supply chain support for clinical and commercial therapeutic assets. Additional responsibilities included resource planning and operations portfolio management.Experience includes engineering & facilities operations, capital project management, process development, manufacturing, innovation, engineering and management positions of increasing responsibility at Amgen, Serono Laboratories, Wyeth, MassBiologics, Biogen, Indigo, Unum, and Enzyvant. Larry has a BS Ch.E. from Tufts University, MBA in Operations & Finance from Babson College, and a Masters in Bioengineering from Tufts. Executive Certificates include Operations & Value Chain Management (MIT) and Drug Development (Harvard). Professional interests include delivering results, enabling innovation, developing people, creating sustainable systems, and creating high-performance teams.
Listed skills include Biotechnology, Validation, Gmp, Manufacturing, and 16 others.